Cord blood granulocyte levels are associated with severe bronchiolitis in the first year of life.

bronchiolitis cord blood eosinophil neutrophil

Journal

Clinical & translational immunology
ISSN: 2050-0068
Titre abrégé: Clin Transl Immunology
Pays: Australia
ID NLM: 101638268

Informations de publication

Date de publication:
Sep 2024
Historique:
received: 17 06 2024
revised: 10 09 2024
accepted: 11 09 2024
medline: 26 9 2024
pubmed: 26 9 2024
entrez: 26 9 2024
Statut: epublish

Résumé

Bronchiolitis is a leading cause of infant hospitalisation in the first year of life, and it preferentially affects infants born to mothers with asthma. Here, we evaluate cord blood granulocytes in infants born to mothers with asthma participating in the Breathing for Life Trial (BLT), to investigate early life determinants of bronchiolitis hospitalisation within the first year of life. Cord blood from 89 participants was collected into EDTA tubes and processed within 6 h of birth. Cells were stained in whole cord blood for eosinophils (CD45 Logistic regression adjusted for caesarean section, gestational age, maternal smoking during pregnancy, foetal heart deceleration during labour, and season of birth revealed an association between cord blood eosinophil levels and bronchiolitis hospitalisation in the first 12 months of life with an Area Under the Curve (AUC) of the Receiver Operating Characteristic (ROC) curve of 0.943 (aOR = 1.35, Higher eosinophil numbers in cord blood were associated with bronchiolitis hospitalisation in the first 12 months in a cohort of infants born to asthmatic mothers. This suggests that susceptibility to bronchiolitis in later life is influenced by the immune cell profile prior to viral infection.

Identifiants

pubmed: 39323541
doi: 10.1002/cti2.70004
pii: CTI270004
pmc: PMC11424167
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e70004

Informations de copyright

© 2024 The Author(s). Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology, Inc.

Déclaration de conflit d'intérêts

The authors declare no conflict of interest.

Auteurs

Gabriela Martins Costa Gomes (G)

Asthma and Breathing Program, Hunter Medical Research Institute The University of Newcastle Newcastle NSW Australia.
School of Medicine and Public Health The University of Newcastle Newcastle NSW Australia.

Carla Rebeca Da Silva Sena (CR)

Asthma and Breathing Program, Hunter Medical Research Institute The University of Newcastle Newcastle NSW Australia.
School of Medicine and Public Health The University of Newcastle Newcastle NSW Australia.

Vanessa E Murphy (VE)

Asthma and Breathing Program, Hunter Medical Research Institute The University of Newcastle Newcastle NSW Australia.
School of Medicine and Public Health The University of Newcastle Newcastle NSW Australia.

Philip M Hansbro (PM)

Centre for Inflammation Faculty of Science, School of Life Sciences, Centenary Institute and University of Technology Sydney Sydney NSW Australia.

Malcolm R Starkey (MR)

Department of Immunology, School of Translational Medicine Monash University Melbourne VIC Australia.

Peter G Gibson (PG)

Asthma and Breathing Program, Hunter Medical Research Institute The University of Newcastle Newcastle NSW Australia.
Department of Respiratory and Sleep Medicine John Hunter Hospital Newcastle NSW Australia.

Joerg Mattes (J)

Asthma and Breathing Program, Hunter Medical Research Institute The University of Newcastle Newcastle NSW Australia.
School of Medicine and Public Health The University of Newcastle Newcastle NSW Australia.
Paediatric Respiratory & Sleep Medicine Department John Hunter Children's Hospital Newcastle NSW Australia.

Adam M Collison (AM)

Asthma and Breathing Program, Hunter Medical Research Institute The University of Newcastle Newcastle NSW Australia.
School of Medicine and Public Health The University of Newcastle Newcastle NSW Australia.

Classifications MeSH